Epoprostenol (PGI2) reduces the incidence of post-reperfusion ventricular fibrillation in the dog.
D000818:Animals; D003327:Coronary Disease / Q000150:complications; D004285:Dogs; D004562:Electrocardiography; D011464:Epoprostenol / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006321:Heart / Q000187:drug effects; D008297:Male; D014693:Ventricular Fibrillation / Q000209:etiology / Q000517:prevention & control*
D011464:Epoprostenol